- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15:11 | Lilly, Merck team with Purdue University to pioneer new drug production methods | ||
| Fr | Novartis wins 11th-hour bid to block generic version of blockbuster heart med Entresto | ||
| Fr | AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions | ||
| Fr | Arvinas' inaugural commercial chief steps down, to be replaced in the interim by market access VP | ||
| Fr | Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy | ||
| Fr | Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations | ||
| Fr | Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value | ||
| Do | Government watchdog recommends tweaks to FDA accelerated approval program | ||
| Do | Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy | ||
| Do | Gilead's Kite taps longtime Amgen alum as new global commercial head | ||
| Do | Atara, Pierre Fabre hit a hurdle with Ebvallo in the US courtesy of manufacturing plant's shortfalls | ||
| Do | Aileron straps in for 2025 with a new name: Rein Therapeutics | ||
| Mi | Lyndra taps Thermo Fisher to help with research, commercial production of long-acting oral meds | ||
| Mi | JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales | ||
| Mi | JPM25, Day 3: AbbVie, UCB, WuXi Biologics and more are set to present | ||
| Mi | JPM25: Amid Samsung Bio's rapid expansion, CDMO weighs plan to build a 6th plant | ||
| Di | JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market | ||
| Di | JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US | ||
| Di | JPM25: Regeneron CEO says it needs more 'arrows in its quiver' as Eylea HD sales fall short | ||
| Di | JPM25, Day 2: GSK, Novartis, Sanofi and Lilly are set to present | ||
| Di | JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales | ||
| Di | Aragen snares $100M investment from Quadria Capital to expand its operations | ||
| 13.01. | Y-mAbs splits from commercial chief, tasks new hire with growing cancer drug sales | ||
| 13.01. | After Alkermes' makeover, CEO Richard Pops touts its pipeline program and rare biotech model | ||
| 10.01. | Lilly doubles down on its presence in India with new capability center, plans to hire 1,000+ |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
